Natural Capsules Limited has released its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company's Board of Directors approved these results on February 13, 2026, based on recommendations from the Audit Committee.

Q3 FY25 Standalone Performance

The company's standalone financial performance for the third quarter of FY25 showed the following results:

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Natural Capsules demonstrated strong operational performance:

Consolidated Results Overview

The consolidated financial results for Q3 FY25 showed total income from operations of ₹146.41 crore and net profit after tax of ₹55.03 crore. For the nine-month period, consolidated total income reached ₹447.73 crore with net profit of ₹201.94 crore.

Financial Position and Capital Structure

The company maintains a stable capital structure with equity share capital of ₹27.13 crore (face value ₹5 per share) remaining consistent across reporting periods. Other equity stood at ₹254.46 crore as of December 31, 2025, resulting in a net worth of ₹281.59 crore. The debt-equity ratio remained low at 0.07.

Business Segments and Operations

Natural Capsules operates in reportable business segments including "Latex Rubber Thread" and "Corrugated Carton Box." The company's subsidiary, Premier Tissues India Limited, operates in the "Paper Tissue" segment. The consolidated results for the nine months ended December 31, 2025, include the financial results of this wholly-owned subsidiary.

Regulatory Compliance and Governance

The company reported no pending investor complaints at the beginning of the quarter. One complaint was received and resolved during the quarter, with no complaints pending at the quarter's end. The financial results were reviewed by the audit committee and approved by the Board of Directors, with auditors issuing an unmodified opinion on the same.

Source: Natural Capsules Limited Financial Results

Natural capsules Limited faced significant operational challenges in Q3FY26, with financial performance reflecting the impact of regulatory disruptions and execution-related headwinds across its business segments. The quarter ended 31st December 2025 marked a difficult period for the hard capsule shell manufacturer and API developer.

Financial Performance Overview

The company's Q3FY26 consolidated results showed substantial declines across key metrics. Revenue contracted to ₹37.75 crore, representing decreases of 18% quarter-on-quarter and 14% year-on-year. More concerning was the shift to negative EBITDA of ₹(2.33) crore compared to ₹7.12 crore in the previous period, resulting in EBITDA margins of (6.16%).

Operational Challenges and Regulatory Impact

The quarter's performance was significantly affected by the temporary shutdown of the Puducherry manufacturing unit following regulatory action relating to the manufacturing licence in December 2025. The regulatory review extended beyond manufacturing to include the sales licence, resulting in deferred dispatches from the facility throughout the quarter.

Management confirmed that the regulatory matter has since been addressed and the Puducherry unit is now operational. Shipments that were delayed during Q3FY26 have been executed in the current quarter, with the spillover expected to positively impact Q4FY26 performance.

Market Developments and Strategic Response

Despite the operational challenges, the company received positive news regarding US market access. The US trade tariffs that had been impacting HPMC capsules have been eased, restoring visibility for growth in the US market and strengthening the outlook for the base capsules business.

Regarding the API segment through subsidiary Natural Biogenex Private Limited, management acknowledged that commercial scale-up of the fermentation block has taken longer than anticipated. While pilot and smaller scale operations demonstrated technical viability, translating this into consistent commercial scale output has presented ongoing challenges.

Strategic Initiatives for Recovery

In response to the fermentation block challenges, Natural Capsules has adopted a calibrated strategy combining internal technical stabilisation efforts with external partnerships. The company has initiated discussions with suitable partners to utilise the fermentation block on a contractual basis, with these discussions reportedly at an advanced stage and initial validation activities undertaken.

Management Outlook

Management noted that input costs and realisations remained stable during the quarter. With both manufacturing plants now running and demand normalising, the company expects meaningful improvement in the current quarter. The leadership expressed confidence that with regulatory issues resolved, US tariff pressures eased, and a structured path forward defined for the fermentation block, the company enters the next quarter with improved operational visibility and a clear strategy to restore growth and profitability.